Article ; Online: Drug allergy desensitization is not a unique recipe.
Current opinion in allergy and clinical immunology
2022 Volume 22, Issue 3, Page(s) 167–174
Abstract: Purpose of review: Drug desensitization is the only therapeutic option for patients with drug allergies who need to receive the drugs they are allergic to, and it is especially critical in patients with an urgent need for chemotherapy, biologics, or ... ...
Abstract | Purpose of review: Drug desensitization is the only therapeutic option for patients with drug allergies who need to receive the drugs they are allergic to, and it is especially critical in patients with an urgent need for chemotherapy, biologics, or antibiotics, where equally effective alternatives might not be available. However, drug desensitization is not a cookbook where anyone with no experience or specific training can find a general recipe. This review article will approach the singularities that make personalized and highly specialized care essential in this field. Recent findings: Drug desensitization needs to be personalized for each individual patient bearing in mind countless factors. Recent articles have tried to define the optimal resources and the most important factors to account for in personalization. However, drug desensitization is only a tool within the wider management pathway, and we will discuss recent findings in allergy delabelling in chemotherapy, biologics, and antibiotics. Summary: Risk-assessment, delabelling, and desensitization protocols, as a part of wider management pathways, can be adapted locally along with comprehensive and multifactorial risk-management strategies. These high-complexity and high-risk procedures, such as drug desensitization, need to be managed by expert allergists who can provide personalization, innovation, continuous improvement, research, and teaching in expert centres. |
---|---|
MeSH term(s) | Anti-Bacterial Agents/adverse effects ; Biological Products ; Desensitization, Immunologic/methods ; Drug Hypersensitivity/diagnosis ; Drug Hypersensitivity/therapy ; Humans |
Chemical Substances | Anti-Bacterial Agents ; Biological Products |
Language | English |
Publishing date | 2022-02-11 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2088710-3 |
ISSN | 1473-6322 ; 1528-4050 |
ISSN (online) | 1473-6322 |
ISSN | 1528-4050 |
DOI | 10.1097/ACI.0000000000000821 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5666: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.